




NRG Publications Committee

Chair: Deborah Watkins Bruner, PhD
Co-chairs: Elizabeth Gore, MD
Thomas Julian, MD
Krish Tewari, MD

NRG Abstract and Manuscript Submissions



Publications in High Impact Journals

Published	Impact Factor	Total 2017	Citation
NEJM	72.406	1	Shipley WU, etal; NRG Oncology RTOG . RT ±Antiandrogen Therapy in Recurrent Prostate Cancer. 2017 Feb 2;376(5):417-428.
Lancet	47.831	2	Tewari KS, etal. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis (GOG240). 2017 Jul 27. pii:S0140-6736(17)31607-0. van den Bent MJ, etal CATNON EORTC glioma trial. Lancet. 2017 Aug 8. pii: S0140-6736(17)31442-3.
JAMA	44.405	0	
Lancet Oncology	33.900	3	Coleman RL etal. Bevacizumab and paclitaxel-carboplatin and secondary cytoreduction in recurrent ovarian (NRG Oncology/GOG) 18(6):779-791. Lacas B, & MARCH Collab. Grp. Role of RT fractionation in H&Nca: meta-analysis. Lancet Oncol. 2017 Sep;18(9):1221-1237. Brown PD, etal. Postop stereotactic radiosurgery vs whole brain RT for resected metastatic disease (NCCTG): 2017;18 (8):1049-1060.
JCO	24.008	6	
JAMA Oncology	16.559	8	
JNCI	12.589	4	
Total		24	


Publications Issues

- Lack of review of Pubs Policy

<https://www.nrgoncology.org/Publications>

- Authorship inclusion confusion
 - Author responsibilities
- Timely draft of publications
- Timely review by co-authors
- Timely signing of COI
- Minimum TWO step process for NIHMS submission
- Requests to submit to predatory publications

NIHMS Compliance


- 1:  Trotti A, Machtay M. [RTOG 9003: legacies of a landmark trial](#). Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):253-4. doi: 10.1016/j.ijrobp.2014.07.022. PubMed PMID: 25304786.

 NIH Public Access Compliance: Non-compliant. No PMCID 3 months post publication. [[Edit Status](#)] NIHMS ID: [NIHMS909452](#)

NIH Funding:

U10 CA021661 - Radiation Therapy Oncology Group

U10 CA180868 - NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER

U10 CA180822 - NRG Oncology Statistical and Data Management Center 

[Add or delete award](#)

<https://www.nrgoncology.org/Publications>
Publications Tab

NRG Oncology Publications Policy and Guidelines

- Pubs Policy v3-23-17

NIH Manuscript Submission Requirements

- What Corresponding Authors Need to Know

Data Sharing Policy

- Data Sharing Policy v12-30-14

Presentation Templates

- PowerPoint Presentation
- Poster Oblong
- Poster Square

WE CAN
HELP YOU



**NRG-Publications@
NRGOncology.org**

Resources Tab

- Ancillary Projects Policy
- Ancillary Projects Application Form
- Data Sharing vs Ancillary Projects Requests
- Review Cycle

NRG Staff Resources

- Central manuscript submission
- Help with NIHMS



NRG NCORP

Principal Investigators

Deborah Watkins Bruner, PhD

Lawrence Wickerham, MD

Joan Walker, MD



Cancer Care Delivery



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
National Cancer Institute
Bethesda, Maryland 20892

Healthcare Delivery Research Program
9609 Medical Center Drive
Bethesda, MD 20892
Telephone (240) 276-6834

December 20, 2017

Deborah Bruner, RN, PhD, FAAN
Principal Investigator
NRG Oncology Research Base
Four Penn Center
1600 JFK Blvd., Suite 1020
Philadelphia, PA 19103

Review of Concept#: NRG-CC1723CD "Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors who Receive Androgen Deprivation Therapy"

Review Date: December 13, 2017

Review Decision: **Approved**

NRG
ONCOLOGY™



Cancer Prevention and Control

	Study No	Disease Site	Description	Date Activated	Target Accrual	Total Accrual	CCOP/NCORP accrual (%)	Target Monthly Accrual	Expected Closure Date
GOG	225	Ovary	Diet and physical activity	6/18/12	1150	1083	21%	17	July 2018
	237	Cervix	CA-IX, P16, markers & HPV in dx of AGC	2/9/09	325 Japan 325 Korea 540 US	325 Japan 321 US 257 Korea	<1%	11	Japan – 3/2016 US – ~4.5 years Korea - ~8 months
RTOG	278	Cervix	before/after non-radical surgery Physical fx & QOL	10/1/12	220	149	<1%	5	December 2020
NRG	CC001	Brain	Memantine and WBRT +/- HA	7/13/15	510	486	79(16%)	9	Feb 2018
	CC003	Lung	Seamless Ph II/III PCI vs. PCI with hippocampal sparing	12/7/15	172 (II) 302 (III)	176	40(23%)	6	Ph II Closed on Oct 13 th
	CC004	Breast, GYN	Ph II double-blinded Bupropion	5/31/17	234	26	26(100%)	10*	N/A

NRG Treatment Trials with PRO Endpoints

- 25/42 (60%) NRG Treatment Trials have PRO Endpoints
- PRO compliance remains an issue
- Compliance working group implementing strategies to address
 - PRO/QOL chairs to monitor more closely and contact sites
 - Protocol/Disease Site Webinars
 - Working on report cards
 - Audits will increase focus on compliance

NCORP RFA

RFAs will likely be released in April or early May.

There are changes to the PHS Human Subjects and Clinical Trial Information forms and NCORP is the first within the NCI clinical trials network to initiate these changes.

- Changes to the PHS form related to clinical trials will be Funding Opportunity Announcement specific

We will have a minimum of 60 days after the release of the RFAs.

- Currently, we are estimating a due date in late summer.

New funding for biobanking to be included

CCD will have increased funding

Transitions and Thank You!



NRG
ONCOLOGY™

David Alberts, MD, CPC



David Cohn, MD, CCD